Fecal Metabolome and the Intestinal Microbiota in Irritable Bowel Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-07-01

Study Completion Date

2023-04-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out the relationship between the bile acids, fatty acids (fatty acids are part of the diet) and bacteria that are present in the intestines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Irritable Bowel Syndrome and Control Volunteers: Diet Challenge

NCT03983434

IBS - Irritable Bowel Syndrome

TERMINATED NA

The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)

NCT01072903

Inflammation Colon, Irritable Colonic Diseases, Functional +1 more

COMPLETED

Diet Reintroduction Study in Irritable Bowel Syndrome

NCT03052439

Irritable Bowel Syndrome

COMPLETED NA

Fecal Microbiota Transplantation in Irritable Bowel Syndrome With Bloating

NCT02299973

Irritable Bowel Syndrome

COMPLETED NA

The Value of Bio-electrical Impedance Analysis in Irritable Bowel Syndrome

NCT05744258

Irritable Bowel Syndrome

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is emerging evidence that alterations in bile acids and SCFA associated with IBS could be associated with changes in the gut microbiota. In addition to modulating levels of intraluminal organic acids, it has been hypothesized that gut microbiota may alter local immune responses, modulate visceral pain responses, and impair gut barrier function.

Our overall goal is to investigate the relationship between fecal bile acids, SCFA and the gut microbiota in IBS. Results of this pilot study could reveal insights into the interplay of the gut microbiota and small molecule mediators of IBS to suggest targeted clinical strategies for improved diagnosis and management of this important syndrome.

AIM 1: Test the hypothesis that fecal organic acids (SFCA and bile acids) and fecal microbiota play an important role in IBS.

AIM 2: Test the hypothesis that there is association between colonic transit and fecal microbiota in IBS

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IBS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IBS-C

all patients with IBS -C will undergo an abdominal x-ray for assessment of colonic transit

X-Ray

Intervention Type RADIATION

X-ray of the abdomen will be performed to assess colonic transit

IBS-D

all patients with IBS-D will undergo an abdominal x-ray for assessment of colonic transit

X-Ray

Intervention Type RADIATION

X-ray of the abdomen will be performed to assess colonic transit

heathy control

all healthy controls will undergo an abdominal x-ray for assessment of colonic transit

X-Ray

Intervention Type RADIATION

X-ray of the abdomen will be performed to assess colonic transit

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

X-Ray

X-ray of the abdomen will be performed to assess colonic transit

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with IBS, ages 18-65 fulfilling Rome IV criteria and asymptomatic controls with no prior history of GI disease or symptoms.
* Participants should be on a stable and consistent diet regimen and should not be following an extreme diet intervention such as gluten-free or a low FODMAP diet at the time of study participation.

Exclusion Criteria

* Participants with microscopic/lymphocytic/collagenous colitis, inflammatory bowel disease, celiac disease, visceral cancer, chronic infectious disease, immunodeficiency, uncontrolled thyroid disease, history of liver disease or history of elevated AST/ALT \> 2.0x the upper limit of normal
* Prior radiation therapy of the abdomen or abdominal surgeries with the exception of appendectomy or cholecystectomy \> 6 months prior to study initiation
* Ingestion of any prescription, over the counter, or herbal medications which can affect GI transit or study interpretation (e.g. opioids, narcotics, anticholinergics, norepinephrine reuptake inhibitors, nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, bile acid sequestrants) within 6 months of study initiation for asymptomatic volunteers or within 2 days before study initiation for IBS patients
* Any females who are pregnant or trying to become pregnant or breast-feeding
* Antibiotic usage within 3 months prior to study participation
* Prebiotic or probiotic usage within the 2 weeks prior to study initiation
* Use of tobacco products within the past 6 months.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes